Status:
COMPLETED
IGF1 Generation Test
Lead Sponsor:
Pfizer
Conditions:
Growth Hormone Deficiency
Eligibility:
All Genders
4-11 years
Phase:
PHASE4
Brief Summary
To assess the predictive value of the short term IGF-1 stimulation test, based on IGF-1 changes, on the 24 months growth response to 2 different doses of GH in patients with conventional GH deficiency...
Eligibility Criteria
Inclusion
- Male or female aged of more than 4 years.
- GHD defined as a peak GH level \< 20 mUI/ml at two different pharmacological GH provocative tests including one done with two pharmacological agents and both performed within the year before the inclusion, according to the current recommendations of the French Health Authorities
Exclusion
- Previous treatment with GH
- Ongoing pharmacological treatment with steroids except if corresponding to substitutive therapy
Key Trial Info
Start Date :
April 1 2001
Trial Type :
INTERVENTIONAL
End Date :
January 1 2005
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT00145457
Start Date
April 1 2001
End Date
January 1 2005
Last Update
June 6 2007
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Besançon, France, 25030
2
Pfizer Investigational Site
Bordeaux, France, 33000
3
Pfizer Investigational Site
Dunkirk, France, 59385
4
Pfizer Investigational Site
Limoges, France, 87042